Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: Implications for antifungal therapy and in Vitro susceptibility breakpoints

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2793-2800

  Sudan, Ajay ^a   Livermore, Joanne ^a,b   Howard, Susan J ^a,b   Al Nakeeb, Zaid ^a   Sharp, Andrew ^a,b   Goodwin, Joanne ^a,b   Gregson, Lea ^a,b   Warn, Peter A ^a   Felton, Tim W ^a,b   Perfect, John R ^c   Harrison, Thomas S ^d   Hope, William W ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; BRAIN; CONTROLLED STUDY; CRYPTOCOCCAL MENINGOENCEPHALITIS; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG BRAIN LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MATHEMATICAL MODEL; MENINGOENCEPHALITIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; FLUCONAZOLE; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MENINGOENCEPHALITIS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 84877846964     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00216-13     Document Type: Article

References (29)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530.
2. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, Wall E, Andia I, Jaffar S, Harrison TS. 2008. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin. Infect. Dis. 47:1556-1561.
3. Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, McCutchan JA, Larsen RA. 2008. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med. Mycol. 46:393-395.
4. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. 2006. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: The role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis. 43:1069-1073.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Schwarz P, Dromer F, Lortholary O, Dannaoui E. 2006. Efficacy of amphotericin B in combination with flucytosine against flucytosinesusceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 50:113-120.
7. Warn PA, Sharp A, Morrissey G, Denning DW. 2005. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. J. Antimicrob. Chemother. 56: 590-593.
8. Andes D, van Ogtrop M. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
9. Kim SS, Im HT, Kang IM, Lee HS, Lee HW, Cho SH, Kim JB, Lee KT. 2007. An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatography with ultraviolet detection and its application to a bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852:174-179.
10. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: Pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
11. Leary R, Jelliffe R, Schumitzky A, van Guilder M. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p 389-394. Proceedings of the Fourteenth IEEE Computer Society, Bethesda, MD.
12. McLachlan AJ, Tett SE. 1996. Pharmacokinetics of fluconazole in people with HIV infection: A population analysis. Br. J. Clin. Pharmacol. 41:291-298.
13. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St. Germain G, Trilles L, Turnidge J. 2012. Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob. Agents Chemother. 56:5898-5906.
14. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS. 2010. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: A randomized trial in Malawi. Clin. Infect. Dis. 50: 338-344.
15. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
16. Palou de Fernandez E, Patino MM, Graybill JR, Tarbit MH. 1986. Treatment of cryptococcal meningitis in mice with fluconazole. J. Antimicrob. Chemother. 18:261-270.
17. Kartalija M, Kaye K, Tureen JH, Liu Q, Tauber MG, Elliott BR, Sande MA. 1996. Treatment of experimental cryptococcal meningitis with fluconazole: Impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J. Infect. Dis. 173:1216-1221.
18. Larsen RA, Bauer M, Weiner JM, Diamond DM, Leal ME, Ding JC, Rinaldi MG, Graybill Jr. 1996. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 40:2178-2182.
19. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM. 1994. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19:741-745.
20. Perfect Jr. 1990. Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. Rev. Infect. Dis. 12(Suppl 3):S299-S302.
21. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JB, Hafner R, Dismukes WE. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and The AIDS Clinical Trials Group. N. Engl. J. Med. 326:83-89.
22. Menichetti F, Fiorio M, Tosti A, Gatti G, Bruna Pasticci M, Miletich F, Marroni M, Bassetti D, Pauluzzi S. 1996. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22: 838-840.
23. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. 2010. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6:e1000848. doi:10.1371/journal.ppat.1000848.
24. Bauer M, Thomas AM, Larsen RA. 2012. Cryptococcus neoformans: The model organism for yeast antifungal drug susceptibility testing. Mycopathologia 173:435-443.
25. Velez JD, Allendoerfer R, Luther M, Rinaldi MG, Graybill Jr. 1993. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J. Infect. Dis. 168:508-510.
26. Larsen RA, Bauer M, Thomas AM, Sanchez A, Citron D, Rathbun M, Harrison TS. 2005. Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. Antimicrob. Agents Chemother. 49:3297-3301.
27. Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MA, Haubrich RH, Richie JA, Edwards JE, Jr, Ghannoum MA. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin. Infect. Dis. 22:322-328.
28. Aller AI, Martin-Mazuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, Gutierrez MJ, Recio FJ, Espinel-Ingroff A. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548.
29. Chin T, Fong IW, Vandenbroucke A. 1990. Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis. Pharmacotherapy 10:305-307.